Phacilitate Match

Phacilitate Match was developed as an on-site event tool geared towards biotech companies who were looking to meet with potential partners. But why limit this to live event matchmaking? In the current climate, we believe that there is no better time for biotech companies to focus on relationship building, and creating connections for both current and future needs.

How does virtual Phacilitate Match work?

- Once you have signed up for virtual Phacilitate Match, you will be contacted by Amanda Kendall, Head of Community here at Phacilitate
- Amanda will ask some profiling questions to understand what suppliers you’re aiming to connect with
- Amanda will present you with organisations that match your needs, from which you can select your priority connections
- Virtual meetings will be arranged on your behalf

By signing up for Phacilitate Match, you will be taking part in a free bespoke service that is completely unique to you. So if you are part of a biotech looking for new contacts, get in touch to see how we can help your company build valuable, lasting connections.
 
PARTICIPATING COMPANIES AT ADVANCED THERAPIES CONNECT
Ares Immunotherapy

Ares Immunotherapy

Ares Immunotherapy is a cellular immunotherapy company with a platform technology for the treatment of solid tumours.

Our intellectual property is based on a unique subset of CD4+CD26+ T-cells that deliver substantial improvements in a solid tumour setting. This potent anti-tumour response is powered by an increased cytokine secretion, improved targeted migration, and prolonged in-vivo persistence driven by a resistance to apoptosis. Our lead candidate is a chimeric antigen receptor (CAR) T-cell targeted against mesothelin and in animal studies we have seen a significant increase in function compared to conventional CAR T leading to tumour regression even up to full tumour ablation. We are preparing for a first in man trial in mesothelioma followed by subsequent trials in other mesothelin containing solid tumours such as lung cancer and pancreatic carcinoma. We have a best-in-class lineup of advisors and an experienced team with decades of cell therapy development experience. 

VISIT WEBSITE
MUVON Therapeutics

MUVON Therapeutics

MUVON Therapeutics is a Swiss biotechnology start-up (planned founding in Q4 2020 -Q1 2021) with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue. Our initial focus is on the treatment of stress urinary incontinence, where we are currently running a phase I clinical trial at the University Hospital of Zurich.
Compared to existing treatment options which have drawbacks ranging from low and short term efficacy to potentially serious adverse events, our novel regenerative approach will provide a safe and effective treatment to millions of people suffering from this highly prevalent condition.

VISIT WEBSITE
Reflection Therapeutics

Reflection Therapeutics

Reflection Therapeutics is creating a first in class treatment for neurodegeneration. Our targetting technology guides CAR-Tregs to vulnerable neurons, protecting them from an overactive immune system.  This prolongs neuronal function and delays disease progression.  Reflection Therapeutics is currently carrying our in vivo proof of concept work in preperation for a seed funding round.

VISIT WEBSITE
Stemson Therapeutics

Stemson Therapeutics

Stemson Therapeutics is a preclinical stage company developing a novel cell therapy to regenerate hair follicles to treat Alopecia and various forms of hair loss.  Stemson was founded in 2018 based on a unique Induced Pluripotent Stem Cell approach to generate the cell types required to initiate hair growth, which was developed by Stemson cofounder, Alexey Terskikh, PhD, in his lab at the Sanford Burnham Prebys Medical Discovery Institute.  The technology has the ability to generate a new supply of hair follicles for patients in need, a capability no other hair loss solution can deliver. The company secured an initial seed funding of $7.5M in 2019 led by Allergan, an Abbvie company, and Fortunis Capital.  Stemson Therapeutics is headquartered in San Diego, CA. 

VISIT WEBSITE